Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)

NCT03498196 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03498196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03498196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Terminated
Start date
December 14, 2018
Completion date
December 9, 2019
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, invasive bladder cancer, metastatic bladder cancer